Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Authors: Holmes FA; Texas Oncology, P.A., US Oncology Research, Houston, TX, USA. Electronic address: faholmesmd@icloud.com., Moy B; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Delaloge S; Institut Gustave Roussy, Villejuif, France., Chia SKL; BC Cancer Agency, Vancouver, BC, Canada., Ejlertsen B; Rigshospitalet, Copenhagen, Denmark., Mansi J; Guy's and St Thomas Hospital NHS Foundation Trust and Biomedical Research Centre, King's College, London, United Kingdom., Iwata H; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan., Gnant M; Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria., Buyse M; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium., Barrios CH; Hospital São Lucas, PUCRS, Porto Alegre, Brazil., Silovski T; Department of Oncology, UHC Zagreb, Zagreb, Croatia., Šeparović R; University Hospital for Tumors, University Hospital Center 'Sestre Milosrdnice', Zagreb, Croatia., Bashford A; Auckland Hospital, Auckland, New Zealand., Zotano AG; Instituto Valenciano de Oncologia, València, Spain., Denduluri N; Virginia Cancer Specialists, US Oncology Research, Arlington, VA, USA., Patt D; Texas Oncology - Round Rock, US Oncology Research, Austin, TX, USA., Gokmen E; Ege University Faculty of Medicine, Izmir, Turkey., Gore I; Alabama Oncology, Birmingham, AL, USA., Smith JW 2nd; Northwest Cancer Specialists, P.C., US Oncology Research, Vancouver, VA, USA., Loibl S; Center for Hematology and Oncology Bethanien, Frankfurt, Germany and German Breast Group, Neu-Isenburg, Germany., Masuda N; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan., Tomašević Z; Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Petráková K; Masaryk Memorial Cancer Institute, Brno, Czech Republic., DiPrimeo D; Puma Biotechnology Inc., Los Angeles, CA, USA., Wong A; Puma Biotechnology Inc., Los Angeles, CA, USA., Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain., Chan A; Breast Cancer Research Centre-WA & Curtin University, Perth, Australia.
Corporate Authors: ExteNET Study Group
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 May; Vol. 184, pp. 48-59. Date of Electronic Publication: 2023 Feb 10.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2023.02.002